What is the history of Cloves Syndrome?

CLOVES syndrome was first described in medical literature in 2007 by Dr. Richard J. Sapp and colleagues, who identified it as a distinct overgrowth disorder characterized by a specific constellation of clinical features. The discovery marked a significant pivot from grouping these patients under the umbrella of Proteus syndrome to recognizing CLOVES syndrome as a unique entity driven by distinct genetic mechanisms.

When was CLOVES syndrome first defined?

Before 2007, patients with CLOVES syndrome were often misdiagnosed with Proteus syndrome or Klippel-Trenaunay syndrome. The acronym CLOVES syndrome (Congenital Lipomatous Overgrowth, Vascular malformations, Epidermal nevi, and Spinal/Skeletal anomalies) was coined to provide a clearer diagnostic framework. Researchers realized that these patients lacked the progressive, aggressive bone overgrowth typical of Proteus syndrome, necessitating a separate classification.

How did genetics change our understanding of CLOVES syndrome?

The landscape of CLOVES syndrome research changed dramatically in 2012 when the underlying cause was identified as a somatic activating mutation in the PIK3CA gene. This discovery moved the condition from a mysterious, idiopathic disorder to a well-defined PIK3CA-Related Overgrowth Spectrum (PROS) condition. This genetic clarity has been vital for the 7 people with CLOVES syndrome currently in our DiseaseMaps community to better understand their diagnosis.

What are the major milestones in treatment?

The evolution of treatment for CLOVES syndrome has shifted from purely surgical management to targeted molecular therapy:

• Surgical Intervention: Historically, debulking surgeries were the only option for managing lipomatous overgrowth.


• PI3K Inhibitors: The development of alpelisib (a PI3K inhibitor) has revolutionized care, offering a way to target the molecular driver of the overgrowth.


• Multidisciplinary Care: Modern clinical management now emphasizes coordinated care between genetics, dermatology, orthopedic surgery, and interventional radiology.

Next steps

• Consult with a clinical geneticist to discuss PIK3CA testing and the latest treatment options.


• Join the CLOVES syndrome community on DiseaseMaps.org to connect with others sharing similar health journeys.


• Review current clinical trials on ClinicalTrials.gov to see if you or your family member are eligible for new therapeutic studies.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): CLOVES syndrome overview.


• Orphanet: Rare disease database entry for CLOVES syndrome.


• OMIM (Online Mendelian Inheritance in Man): PIK3CA-related overgrowth spectrum.


• CLOVES Syndrome Community: Patient advocacy and research foundation resources.